207557-34-4

Basic information

• Product Name: N-(2-aminoethyl)-N-[5-(trifluoromethyl)pyridin-2-yl]amine
• Synonyms: N-(2-aminoethyl)-N-[5-(trifluoromethyl)pyridin-2-yl]amine
• CAS NO: 207557-34-4
• Molecular Formula: C8H10F3N3
• Molecular Weight: 205.1803096
• Mol File: 207557-34-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 291.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.316±0.06 g/cm3(Predicted)
• PKA: 9.08±0.10(Predicted)
• CAS DataBase Reference: N-(2-aminoethyl)-N-[5-(trifluoromethyl)pyridin-2-yl]amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-aminoethyl)-N-[5-(trifluoromethyl)pyridin-2-yl]amine(207557-34-4)
• EPA Substance Registry System: N-(2-aminoethyl)-N-[5-(trifluoromethyl)pyridin-2-yl]amine(207557-34-4)

Safety Data

• Hazardous Substances Data: 207557-34-4(Hazardous Substances Data)

Upstream product

• 107-15-3 ethylenediamine 
• 50488-42-1 2-bromo-5-(trifluoromethyl)pyridine 
• 69034-12-4 2-chloro-5-(trifluoromethyl)pyrimidine 
• 52334-81-3 2-chloro-5-trifluoromethylpyridine 

Downstream Products

• 286008-58-0 N-(5-Chloro-6-methyl-2-pyridin-2-yl-pyrimidin-4-yl)-N'-(5-trifluoromethyl-pyridin-2-yl)-ethane-1,2-diamine 

Relevant articles and documents

Novel Pyrimidine- And Triazine-Hepcidine Antagonists

The present invention relates to new hepcidin antagonists, pharmaceutical compositions containing them and the use thereof as a drug, in particular for the treatment of iron metabolism disorders such as, in particular, iron deficiency diseases and anaemia, in particular anaemia associated with chronic inflammatory disease (ACD: anaemia of chronic disease and AI: anaemia of inflammation).

Inhibitors of glycogen synthase kinase 3

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.